Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nanobac Pharmaceuticals Inc (PK:NNBP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 5025 W Lemon St
TAMPA FL 33609-1101
Tel: N/A
Website: N/A
IR: N/A
Key People
John D. Stanton
Chairman of the Board, Chief Executive Officer, Chief Financial Officer
   
Business Overview
Nanobac Pharmaceuticals, Incorporated (Nanobac) is a research-based, bio-lifescience company. The Company is primarily engaged in the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. Its research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac's drug discovery and development is focused on new and existing compounds that inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, antibodies and reagents for recognizing CNPs.
Financial Overview
For the fiscal year ended 31 December 2007, Nanobac Pharmaceuticals, Inc. revenues decreased 92% to $18K. Net loss increased 32% to $6.6M. Revenues reflect United States segment decrease of 100% to $1K, Other Foreign segment decrease of 19% to $17K. Higher net loss reflects Loss on Early Extinguishment of Debt increase from $0K to $1.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.02 to -$0.03.